On May 28, Sagent Pharmaceuticals announced the recall of two lots of docetaxel injection, USP (80 mg per 8 mL and 160 mg per 16 mL multidose vials).
The recall is due to a customer complaint of the potential presence of particulate matter from the stopper in the product. The recalled lots were distributed nationwide by Sagent from Oct. 11, 2023, to April 11, 2024.
In a Sagent announcement posted by the FDA, the company warned that patients who receive an IV administration of an injectable